Scaffolds to treat solid tumor cells and escape variants
AssigneeFred Hutchinson Cancer Research Center
InventorsMatthias Stephan, Colin Patrick Kealey
Life of this patent
Estimating the term…
Abstract
Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte activating moiety.
Claims205
A lymphocyte scaffold comprising (i) genetically-reprogrammed lymphocytes disposed within a scaffold matrix comprising thin film nitinol (TFN) micromesh, (ii) a lymphocyte-adhesion moiety comprising fibrin, and (iii) lymphocyte-activating moieties comprising antibodies specific for CD137.
A lymphocyte scaffold comprising (i) genetically-reprogrammed lymphocytes disposed within a scaffold matrix comprising a micropatterned metallic thin film, and (ii) a lymphocyte-activating moiety.
A lymphocyte scaffold consisting of a scaffold matrix, genetically reprogrammed lymphocytes, and three lymphocyte-activating moieties.
A lymphocyte scaffold comprising:
- a scaffold matrix, genetically-reprogrammed lymphocytes, and a lymphocyte-activating moiety.
A lymphocyte scaffold comprising:
- (i) a scaffold matrix comprising an alginate scaffold;
- (ii) genetically-reprogrammed lymphocytes;
- (iii) a lymphocyte-adhesion moiety comprising a GFOGER (SEQ ID NO:
- 1) peptide;
- (iv) lymphocyte-activating moieties comprising antibodies specific for CD3, CD28, and CD137;
- and
- (v) a STING agonist.
A lymphocyte scaffold comprising:
- (i) a scaffold matrix material, (ii) natural killer cells with anti-cancer activity, and (iii) lymphocyte-activating moieties comprising IL-15 and an antibody specific to CD137.
A method of treating a subject for cancer comprising implanting into the subject a medical device coated with a lymphocyte scaffold comprising a TFN micromesh, genetically-modified lymphocytes, and a lymphocyte activating moiety.
A kit to form a lymphocyte scaffold to treat a solid tumor in a subject comprising (i) a scaffold matrix;
- and (ii) lymphocyte-activating moieties comprising antibodies specific for CD3, CD28, and CD137.
A kit to form a lymphocyte scaffold comprising:
- (i) a scaffold matrix comprising TFN micromesh (ii) a lymphocyte-adhesion moiety comprising fibrin;
- and (iii) lymphocyte-activating moieties comprising antibodies specific for CD3, CD28, and CD137.
A kit to form a lymphocyte scaffold comprising:
- (i) a scaffold matrix comprising an alginate scaffold, (ii) a lymphocyte-adhesion moiety comprising a GFOGER (SEQ ID NO:
- 1) peptide, (iii) lymphocyte-activating moieties comprising antibodies specific for CD3, CD28, and CD137, and (iv) a STING agonist.
An implantable medical device comprising:
- (i) a micropatterned metallic thin film scaffold, (ii) genetically reprogrammed lymphocytes, and (iii) a lymphocyte-activating moiety.
The implantable medical device of claim 1967, comprising a minimally invasive medical device.
Dependencies are inferred from the claim text.